Metaplastic Breast Cancer: A Review.

[1]  R. Gray,et al.  A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609) , 2021, Clinical Cancer Research.

[2]  S. Bandyopadhyay,et al.  Clinicopathologic Characteristics and Outcome Descriptors of Metaplastic Breast Carcinoma. , 2021, Archives of Pathology & Laboratory Medicine.

[3]  S. Ganesan,et al.  Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer , 2021, Case Reports in Oncology.

[4]  H. McArthur,et al.  A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy , 2021, Frontiers in Oncology.

[5]  H. Abdel-Razeq,et al.  Metaplastic Breast Carcinoma: Experience of a Tertiary Cancer Center in the Middle East , 2021, Cancer control : journal of the Moffitt Cancer Center.

[6]  San-Gang Wu,et al.  The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma , 2020, Scientific Reports.

[7]  Jamie R. Kutasovic,et al.  Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1 , 2020, British Journal of Cancer.

[8]  J. Pérez-García,et al.  Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma , 2020, Cancers.

[9]  Alexey I. Nesvizhskii,et al.  Quantitative proteomic landscape of metaplastic breast carcinoma pathological subtypes and their relationship to triple-negative tumors , 2020, Nature Communications.

[10]  Masayuki Yoshida,et al.  Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation , 2020, Case reports in oncological medicine.

[11]  P. Fasching,et al.  Pembrolizumab for Early Triple-Negative Breast Cancer. , 2020, The New England journal of medicine.

[12]  A. Salomon,et al.  Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers , 2020, Journal of Hematology & Oncology.

[13]  G. Babiera,et al.  Outcomes after Treatment of Metaplastic Versus Other Breast Cancer Subtypes , 2020, Journal of Cancer.

[14]  H. Wathieu,et al.  Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor , 2019, bioRxiv.

[15]  C. Kleer,et al.  Metaplastic Breast Carcinoma: Update on Histopathology and Molecular Alterations. , 2019, Archives of pathology & laboratory medicine.

[16]  E. B. Butler,et al.  Comparison of outcomes between metaplastic and triple-negative breast cancer patients , 2019, Breast.

[17]  San-Gang Wu,et al.  The Effect of Post-mastectomy Radiotherapy in Patients With Metaplastic Breast Cancer: An Analysis of SEER Database , 2019, Front. Oncol..

[18]  D. Visscher,et al.  Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy , 2019, Breast cancer research and treatment.

[19]  H. Nevanlinna,et al.  Metaplastic carcinoma of the breast: Prognosis and response to systemic treatment in metastatic disease , 2019, The breast journal.

[20]  J. Niland,et al.  Molecular characterization of metaplastic breast carcinoma via next-generation sequencing. , 2019, Human pathology.

[21]  F. Esteva,et al.  Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis , 2018, Breast Cancer Research and Treatment.

[22]  C. Perou,et al.  Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel , 2018, Clinical Cancer Research.

[23]  Yunni-Yi Chen,et al.  Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma , 2018, Modern Pathology.

[24]  T. Hyslop,et al.  Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database , 2018, Annals of Surgical Oncology.

[25]  Xiaomeng Gong,et al.  Metaplastic breast carcinoma: a clinical analysis of 26 cases. , 2018, International journal of clinical and experimental pathology.

[26]  K. Glazebrook,et al.  Management of the axilla in metaplastic breast carcinoma. , 2018, Gland surgery.

[27]  Z. Shao,et al.  Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: A large population-based analysis. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[28]  E. B. Butler,et al.  Metaplastic Breast Cancer: Practice Patterns, Outcomes, and the Role of Radiotherapy , 2018, Annals of Surgical Oncology.

[29]  T. Khoury,et al.  Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple‐negative Breast Cancer: A Study From a Single Institution and Review of Literature , 2017, Clinical breast cancer.

[30]  B. Calhoun,et al.  Predictive factors on outcomes in metaplastic breast cancer , 2017, Breast Cancer Research and Treatment.

[31]  I. Ellis,et al.  Immunoprofile of metaplastic carcinomas of the breast , 2017, Histopathology.

[32]  A. Cimino-Mathews,et al.  Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component , 2017, Clinical Cancer Research.

[33]  K. Hess,et al.  Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab , 2017, JAMA oncology.

[34]  S. Adams.  Dramatic response of metaplastic breast cancer to chemo-immunotherapy , 2017, npj Breast Cancer.

[35]  P. Tan,et al.  Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer , 2017, Breast Cancer Research and Treatment.

[36]  O. Mariani,et al.  The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas , 2017, Clinical Cancer Research.

[37]  E. Kotteas,et al.  Management and Outcomes in Metaplastic Breast Cancer. , 2016, Clinical breast cancer.

[38]  J. Palazzo,et al.  Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1 , 2016, Journal of Clinical Pathology.

[39]  E. Rakha,et al.  Imaging overview of metaplastic carcinomas of the breast: a large study of 71 cases. , 2016, The British journal of radiology.

[40]  P. Argani,et al.  A Clinicopathologic Analysis of 45 Patients With Metaplastic Breast Carcinoma. , 2016, American journal of clinical pathology.

[41]  Guangliang Yin,et al.  Whole exome sequencing of rare aggressive breast cancer histologies , 2016, Breast Cancer Research and Treatment.

[42]  Shuai Li,et al.  Clinicopathological Features and Prognosis of Metaplastic Breast Carcinoma: Experience of a Major Chinese Cancer Center , 2015, PloS one.

[43]  I. Huijbers,et al.  Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer , 2015, Proceedings of the National Academy of Sciences.

[44]  P. Stephens,et al.  Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options. , 2015, Archives of pathology & laboratory medicine.

[45]  J. Lee,et al.  Unique characteristics and failure patterns of metaplastic breast cancer in contrast to invasive ductal carcinoma: a retrospective multicenter case-control study (KROG 13-07). , 2015, Clinical breast cancer.

[46]  C. Pérez-Plasencia,et al.  Metaplastic breast cancer: a comparison between the most common histologies with poor immunohistochemistry factors , 2015, BMC Cancer.

[47]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[48]  T. Koehler,et al.  Hormone Receptor Status Does Not Affect Prognosis in Metaplastic Breast Cancer: A Population-Based Analysis with Comparison to Infiltrating Ductal and Lobular Carcinomas , 2014, Annals of Surgical Oncology.

[49]  P. Sharma,et al.  PD-L1 Expression in Triple-Negative Breast Cancer , 2014, Cancer Immunology Research.

[50]  R. Nelson,et al.  Survival Outcomes of Metaplastic Breast Cancer Patients: Results from a US Population-based Analysis , 2014, Annals of Surgical Oncology.

[51]  Yanlv Ren,et al.  Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators , 2013, World Journal of Surgical Oncology.

[52]  B. Choi,et al.  Metaplastic carcinoma of the breast: multimodality imaging and histopathologic assessment , 2012, Acta radiologica.

[53]  I. Turker,et al.  Metaplastic breast carcinoma: case series and review of the literature. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[54]  Chiun-Sheng Huang,et al.  Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era , 2011, Breast Cancer Research and Treatment.

[55]  V. Valero,et al.  Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers , 2011, Breast Cancer Research and Treatment.

[56]  H. Park,et al.  Clinicopathologic Features and Outcomes of Metaplastic Breast Carcinoma: Comparison with Invasive Ductal Carcinoma of the Breast , 2010, Yonsei medical journal.

[57]  S. Martinez,et al.  Metaplastic Breast Cancer: To Radiate or Not to Radiate? , 2010, Annals of Surgical Oncology.

[58]  Byung-Ho Nam,et al.  Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer , 2010, Breast Cancer Research and Treatment.

[59]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[60]  Nicholas J. Wang,et al.  Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. , 2009, Cancer research.

[61]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[62]  N. Sneige,et al.  Imaging differences in metaplastic and invasive ductal carcinomas of the breast. , 2007, AJR. American journal of roentgenology.

[63]  K. Bland,et al.  Characteristics and Treatment of Metaplastic Breast Cancer: Analysis of 892 Cases from the National Cancer Data Base , 2006, Annals of Surgical Oncology.

[64]  J. Beatty,et al.  Metaplastic breast cancer: clinical significance. , 2006, American journal of surgery.

[65]  L. Lai,et al.  Metaplastic Breast Cancer: Clinical Features and Outcomes , 2005, The American surgeon.

[66]  Gerolama Condorelli,et al.  PED mediates AKT-dependent chemoresistance in human breast cancer cells. , 2005, Cancer research.

[67]  C. Romagosa,et al.  MRI of metaplastic carcinoma of the breast. , 2005, AJR. American journal of roentgenology.

[68]  G. Mills,et al.  HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells , 2003, Oncogene.

[69]  J. Simpson,et al.  Metaplastic breast tumors with a dominant fibromatosis‐like phenotype have a high risk of local recurrence , 1999, Cancer.

[70]  J. Ingle,et al.  Metaplastic breast cancer: prognosis and response to systemic therapy. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  H. Gutman,et al.  Biologic distinctions and therapeutic implications of sarcomatoid metaplasia of epithelial carcinoma of the breast. , 1995, Journal of the American College of Surgeons.

[72]  H. Norris,et al.  Metaplastic carcinomas and sarcomas of the breast. , 1991, American journal of clinical pathology.

[73]  H. Norris,et al.  Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin , 1990, Cancer.

[74]  H. Norris,et al.  Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. , 1989, Human pathology.

[75]  H. Norris,et al.  Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. , 1989, Human pathology.

[76]  P. Rosen,et al.  Low-Grade Adenosquamous Carcinoma: A Variant of Metaplastic Mammary Carcinoma , 1987, The American journal of surgical pathology.